Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 3/20 | 0.56 |
| ▸ | NPY4R | P50391 | 4/20 | 0.54 |
| ▸ | NPY1R | P25929 | 3/20 | 0.54 |
| ▸ | NPY2R | P49146 | 3/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5032917 | 0.99 | ENPEP (0.56) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL30252225 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL29948864 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL266555 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL266554 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL4293356 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL29365741 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL4293347 | 0.98 | NPY4R (0.54) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL31467474 | 0.95 | ERAP2 (0.55) | ENPEPNPY4RNPY1RNPY2RERAP2 | |
| SCHEMBL27906627 | 0.94 | ENPEP (0.52) | ENPEPNPY4RNPY1RNPY2RERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040729-A2 | ATTENUATION OF REPERFUSION INJURY | Alavita Pharmaceuticals, Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008561-A2 | ATTENUATION OF REPERFUSION INJURY | ALAVITA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2004013303-A2 | MODIFIED ANNEXIN PROTEINS AND METHODS FOR TREATING VASO-OCCLUSIVE SICKLE-CELL DISEASE | SURROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |